A Phase II Baseline Versus Treatment Study to Determine the Efficacy of Raltegravir (Isentress) in Preventing Progression of Relapsing Remitting Multiple Sclerosis as Determined by Gadolinium-enhanced MRI

Trial Profile

A Phase II Baseline Versus Treatment Study to Determine the Efficacy of Raltegravir (Isentress) in Preventing Progression of Relapsing Remitting Multiple Sclerosis as Determined by Gadolinium-enhanced MRI

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Raltegravir (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms INSPIRE
  • Most Recent Events

    • 01 Nov 2016 Results (n=20) assessing efficacy published in the Clinical Drug Investigation.
    • 28 Apr 2015 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
    • 31 Oct 2014 Accrual to date is 121% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top